Trushdeep Agrawal, Founder at Association of Physicians & Engineers and Peer Reviewer at Wolters Kluwer, shared on LinkedIn about a paper he authored published in Sage and ISOPP:
“Ensartinib was approved in December 2024. I started reading relevant literature in the following months and decided to conduct a review of the trials.
My paper has been published in the Journal of Oncology Pharmacy Practice (Sage Publications), the official journal of the International Society of Oncology Pharmacy Practitioners (ISOPP).
Highlights from the Paper:
- Ensartinib is a highly effective and tolerable option for ALK-positive NSCLC.
- 5 Major Clinical Trials were included.
- Limitation: the open-label nature of most included studies.
- The inconsistent responses among various molecular subgroups and the need for long-term outcome data shows the necessity for continued investigation.
I want to thank the following for their support throughout:
Dr. Rajendrasingh Arora (Director, Amravati Cancer Foundation),
Dr. Varsha Agrawal (Head of Palliative Care, Amravati Cancer Foundation), Dr. Hariharan Seshadri, Mr. Swastik Pandita and Ms. Debasmita Das.”
Title: Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
Author: Trushdeep Agrawal
You can read the full article in Journal of Oncology Pharmacy Practice.
More posts featuring Trushdeep Agrawal.